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Abstract— Pituitary tumours account for ~16% of central 
nervous system tumors and they are the second most frequently 
reported histology in this group. Due to their small size, pituitary 
surgery is challenging and precise lesion localization through 
imaging is therefore a critical factor for a successful outcome. 
Simultaneous PET/MR is well suited for lesion identification and 
localization but it requires accurate attenuation correction to 
ensure optimal PET imaging. Atlas-based attenuation correction 
methods are often used for this purpose, as they overcome the 
difficulty of estimating bone tissue density with conventional MR 
sequences. However, atlas methods can only partially account for 
inter-patient variability. 
The goal of the present study was to investigate whether direct 
bone measurement, by means of a zero echo time (ZTE) MR 
sequence, can significantly improve the accuracy of pituitary 
tumor imaging with PET. 
 
Index Terms— ZTE, PET/MR, attenuation, pituitary 
INTRODUCTION 
The pituitary gland, or hypophysis, is an endocrine gland located at 
the base of the brain, suspended from the hypothalamus by a gray 
matter stalk. It is housed by the hypophysial fossa of the sphenoid 
bone, at the center of the middle cranial fossa. The pituitary gland is 
approximately 13 mm in diameter and 5 mm of height, weighing 500 
mg. In humans, the pituitary gland consists of two main lobes, anterior 
and posterior, each releasing specific hormones that affect several 
bodily functions.  
Given its key role in overall metabolic regulation, the effects of 
tumoral lesions in the pituitary gland can have devastating effects in 
both health and quality of life. Pituitary tumors include slow-growing 
benign pituitary adenomas, invasive pituitary adenomas -which may 
spread to neighboring structures- and malignant pituitary carcinomas -
which may create metastases in the central nervous system or remote 
organs-.  
According to the Central Brain Tumor Registry of the United States 
[1], tumors of the pituitary gland account for ~16% of central nervous 
system tumors (rate 3.98 per 100,000), with only a minimal fraction of 
these being malignant (rate 0.01 per 100,000). Tumors of the pituitary 
are the second most frequently reported histology (16.2%).  
Treatment options for pituitary tumors include surgery, drugs and 
radiation therapy, with partial excision of the pituitary gland via trans-
sphenoidal surgery (TSS) being the most common. The standard 
detection procedure is magnetic resonance imaging (MRI) of the sella 
turcica region. Recent work has shown 11C-Methionine positron 
emission imaging (PET) to provide valuable complementary 
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information: E.g. to identify residual adenoma in patients with 
persistent acromegaly after therapy [2] or to facilitate targeted surgical 
therapy of corticotropin-secreting tumors in Cushing's syndrome [3], 
as well as radiosurgery planning and radiotherapy [4]. 
Hybrid Positron Emission Tomography and Magnetic Resonance 
Imaging (PET/MR) is an emerging modality, introduced for clinical 
use in 2011. There are a number of reasons suggesting that PET/MR 
could become the modality of choice for pituitary lesion imaging:  
First, the availability of perfectly co-registered anatomical and 
functional data in a single examination. Given the size of the pituitary 
gland and its critical role in overall metabolic function, there is very 
little margin of error when planning partial surgical excision. Precise 
lesion localization and delimitation through imaging are therefore a 
critical success factor. Good co-registration is even more necessary 
when dealing with complex abnormal structures, such as the follow-up 
of patients not responding to surgical treatment.  
Furthermore, the extremely low rate of malignancy makes this 
indication ideal for focused –as opposed to whole-body– imaging. 
Fully integrated PET and MR systems excel at this particular task, as 
the extended scan time required to acquire multiple complementary 
MR sequences can be effectively exploited by PET. The additional 
time can be used to either increase the quality of the acquired PET data, 
reduce the required radiotracer dose or perform kinetic analysis of 
tracer dynamics.  
One of the main challenges of PET/MR imaging is attenuation 
correction. Quantitative PET imaging requires compensating for the 
signal attenuation introduced by the patient. In PET/CT scanners, this 
is estimated from the X-ray attenuation data provided by the computed 
tomography (CT) scan. In the absence of CT data, PET/MR scanners 
must rely on relatively complex segmentation procedures to identify 
different tissue classes (e.g. fat, soft tissue, lung, etc.) and assign them 
a priori attenuation coefficients [5], [6]. 
In the particular case of head imaging, the identification of bone 
tissue is a determining factor of the final PET accuracy [7]. However, 
MR is not an ideal modality for bone imaging: cortical bone yields 
signals that are weak, due to the low proton density (~20% of water), 
and short-lived, due to the heterogeneous structure (T2 ~ 390µs at 
3T)[8]. The incorporation of anatomical atlas information into the 
attenuation correction process is often used to overcome this obstacle 
[9]–[11]. 
While atlas-based attenuation correction methods have been shown 
to result in usable PET reconstructions for routine clinical imaging 
[12]–[15], they are also known to conform sub-optimally to each 
patient’s anatomical variability. Atlas methods also have a limited 
ability to account for off-norm anatomies, such as those caused by 
pathology or surgical alteration. As an alternative to the use of a priori 
anatomical models, short echo time sequences have been proposed for 
direct bone imaging with MR [16], [17]. In particular, 3D radial zero 
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echo time (ZTE) imaging has been proven to provide high-resolution 
isotropic images, suitable for bone segmentation [18]–[20].  
The goal of the present study is to investigate whether direct bone 
measurement with ZTE can significantly improve the accuracy of 
pituitary tumor imaging in PET/MR. We hypothesize that, due to its 
structurally complex location, surrounded by a small bony cavity (sella 
turcica) and in close proximity to a cavity (sphenoid sinus), 
conventional atlas registration methods are not accurate enough to 
account for the inter-patient variability of this region.  
MATERIALS AND METHODS 
Data acquisition was performed at Addenbrooke’s Hospital 
(Cambridge, UK) within the context of a sponsored study for the 
development of new methods for pituitary tumor diagnosis and 
treatment. This study was approved by the institutional review board.  
A. Patients 
Twenty-five subjects were recruited between June 2017 and May 
2018: 10 male, 15 female; age 41 ± 14, range 20 to 70; weight 85 ± 22 
kg, range 54 to 158 kg. All subjects were adults, referred for a 
clinically indicated PET/CT. Exclusion criteria were the standard 
contraindications of MR imaging as well as claustrophobia or body 
habitus not compatible with the 60 cm bore of the PET/MR scanner. 
Of the above, 14 patients returned 28 ± 1 days later for a post-therapy 
session. All subjects provided signed informed consent prior to the 
examinations. 
B. Data acquisition 
All subjects were required to fast for a minimum of 4 hours prior to 
the injection of the radiotracer. Before the PET/CT examination, they 
were injected intravenously with 412 ± 39 MBq of 11C-Methionine, 
range 301 to 442 MBq. The acquisition took place 19 ± 2 min, range 
14 to 25 minutes after tracer administration 
The PET/CT acquisition (Discovery 690 PET/CT, GE Healthcare) 
followed the site’s default protocol for pituitary imaging. First, a 
helical CT scan was acquired: 140 kV, 220 mAs, matrix size 512×512, 
slice thickness 1.25 mm, field of view 300 mm, pixel size 0.59×0.59 
mm2. Subsequently, a single-bed brain PET dataset, not relevant for the 
present study, was acquired for 20 minutes.  
Immediately after the PET/CT scan, patients were transferred to the 
integrated PET/MR scanner (SIGNA PET/MR, GE Healthcare). There 
was no additional radiotracer injection for the PET/MR. The 
acquisition took place 76 ± 20 min, range 57 to 113 minutes, after 
tracer administration. The patient setup included a 32-channel brain 
coil (Nova Medical Inc., Wilmington, MA). A 40-minute PET 
acquisition was performed.  
A number of MR sequences were acquired simultaneously with the 
PET acquisition. For attenuation correction purposes, the default 
LAVA-Flex sequence [21] was automatically prescribed by the 
system: axial acquisition, repetition time ~4 ms, echo time 1.12 ms & 
2.23 ms, flip angle 5°, slice thickness 5.2 mm, matrix 256 × 256 × 120, 
voxel size 1.95 × 1.95 × 2.60 mm3, number of averages 0.7, acquisition 
time: 18 s. Additionally, a prototype zero echo time (ZTE) sequence 
was acquired for bone identification (25): 3D radial acquisition, flip 
angle 0.8°, matrix 110 × 110 × 116, voxel size 2.4 × 2.4 × 2.4 mm3, 
number of averages 4, bandwidth ±62.5 kHz, acquisition time 42 s. 
Several diagnostic sequences were included in the protocol (e.g. T1 
BRAVO, T2 CUBE, FOCUS DWI, etc.). All acquisitions used body 
coil transmit and the 32-channel brain coil for receive, except the 
attenuation correction LAVA-Flex, which used body coil transmit and 
receive. 
C. Attenuation Map generation 
For each patient, three attenuation correction (AC) maps were 
generated: The default atlas-based map recommended by the 
manufacturer for brain imaging; a ZTE-based map; and a CT-based 
map, to be used as gold standard.  
The Atlas-AC map was generated automatically by the system’s 
default brain PET reconstruction [22]: A non-rigid B-spline method is 
used to register a CT-based head atlas to the LAVA-Flex images. The 
resulting volume is automatically rescaled to annihilation photon 
attenuation coefficients and combined with templates of the bed and 
Nova 32-channel head coil attenuation.   
The ZTE-based attenuation map was generated using a custom 
algorithm implemented in C++ using ITK (Kitware Inc., Clifton Park, 
NY): The algorithm includes pre-filtering, histogram-based 
normalization, intensity-based extraction of a head mask, bias 
correction, extraction of region of interest masks (paranasal sinuses, 
bone tissue, air cavities and partial volume) and pseudo-CT generation 
by piece-wise linear mapping of the bias-corrected ZTE intensity 
values  [23]. Soft tissue is assigned a constant value of 42 HU, whereas 
bone tissue is linearly scaled based on the ZTE intensity: pCT = 42 – 
2400 × (ZTE - 1). The resulting pseudo-CT is then re-sampled to the 
appropriate resolution for PET attenuation correction (matrix 128 x 
128 x 89 voxels, 4.69 x 4.69 x 2.78 mm3).  Finally, the hardware 
attenuation templates are extracted from the attenuation map obtained 
with the Atlas method and merged into the ZTE-based map. 
The CT-based attenuation map was generated using custom Matlab 
(Mathworks, Natick, MA) scripts: The procedure involves an 
interactive CT cleanup step, where unwanted structures (such as the 
arms and CT hardware) are removed. The resulting dataset is then 
automatically registered to the pseudo-CT series generated by the ZTE 
processing, using a rigid transform and mono-modal metric. 
Registration results are visually verified in each case (this simple 
method has been found to be robust and accurate for the cranium). The 
remaining steps are equivalent to those used to transform the ZTE 




Fig. 1. Sagittal views of the reconstructed 11C-Methionine PET images 
using each of the attenuation correction methods. Notice the hot spot on 




Fig. 2. Axial views of the final attenuation maps generated with each of 
the tested methods.  
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D. Retrospective PET reconstruction 
PET/MR sinogram data were retrospectively reconstructed using a 
Matlab toolbox provided by GE Healthcare, which implements the 
same reconstruction algorithms used in the scanner. A separate 
reconstruction was performed with each of the three attenuation maps 
(PETatl, PETZTE and PETCT). The reconstruction parameters were selected 
to mimic those of the PET/CT clinical protocol, while accounting for 
the limitations imposed by the different detector geometry: Fully 3D 
ordered subsets expectation maximization algorithm with time-of-
flight information (VPFX), iterations 9, subsets 8, matrix 128 × 128 × 
89, voxel size 2.34 × 2.34 × 2.78 mm3, transaxial post-reconstruction 
Gaussian filter 4mm, axial filter 1:2:1, point-spread function, 
normalization, randoms, scatter, dead-time and decay corrections. 
 
 
Fig. 3. Surface rendering of a pituitary gland, segmented from MR, fused 
with the corresponding 11C-Met PET uptake. Notice how PET clearly 
indicates the laterality of the lesion, with respect to the centrally-located 
pituitary stalk. Surface renderings of the carotid arteries are provided for 
surgical guidance. 
RESULTS 
All exams were successfully completed without relevant incidents. 
The automated post-processing and reconstruction steps performed as 
expected without the need for manual corrections. Fig. 1 illustrates the 
results of a 11C-Met PET reconstruction, with each attenuation map. 
The initial ZTE processing was found to over-estimate the axial 
sensitivity range of the brain coil by ~1 cm and had to be fixed. Aside 
from this, no gross abnormalities or artifacts were detected on the 
attenuation maps. Figure 2 shows an example of the attenuation maps 
obtained with each of the three methods. 
The reconstructed PET images were reviewed by an endocrinologist 
(W.B) and a radionuclide radiologist (I.M.), both with prior experience 
reading pituitary PET data, to determine the presence and location of 
Methionine-avid lesions. All reconstructions were judged to be 
suitable for the purpose of diagnosis of the pituitary. Figure 3 shows 
an example of pathological 11C-Met PET uptake overlaid on MR-based 
surface renderings of the pituitary gland and carotid arteries. The 
identified pathologies included Cushing’s disease (48%), thyrotropin-
secreting pituitary adenoma (20%), acromegaly (12%), non-
functioning pituitary adenoma (12%), prolactinoma (4%).   Tumor 
volumes ranged from 195 mm3 to 6702 mm3, with an average of 1452 
mm3 and median of 375 mm3. 
Voxel-wise difference images between the PET images 
reconstructed with MR-based attenuation correction methods (PETatl, 
PETZTE) and the reference reconstruction using CT-based attenuation 
correction (PETCT) were calculated. Figure 4 shows the obtained 
differences for a representative case. While a consistent improvement 
in brain uptake accuracy was appreciated for the ZTE-based method, 
consistent with previous reported studies [23], [24], the results were 
more erratic in the pituitary region, with moderate improvements and 
some instances of increased error near anatomical boundaries. 
 
 
Fig. 4. Sagittal views of the differences in uptake between PET images 
reconstructed with each of the MR-based attenuation correction 
methods and the reference PET reconstruction with CT-based 
attenuation correction.  
 
To obtain bias measurements specific to the region of interest, the 
pituitary gland and cerebellum were manually segmented on MR 
FSPGR images. The resulting masks were used to generate normalized 
uptake (SUVR) measurements. For each PET reconstruction, the mean 
and maximum uptake on the pituitary gland were calculated, as well as 
the average position of the hot-spot relative to the pituitary gland mask. 
Figure 5 summarizes the obtained mean SUVR results. Those cases 
without a clear hot-spot (7 of 25) were discarded from the subsequent 
analysis.  







The reconstructions with the ZTE-based method were found to 
match the reference (PETCT) in terms of mean SUVR with similar 
accuracy as their atlas-based counterparts, but considerably more 
precision. Tables I and II summarize these findings. 
Shifts larger than 10% between the average lesion positions were 
identified in five cases: twice in PETatl, twice PETZTE and once in both 
(with the same value). Visual inspection of these cases showed low-
frequency modulations of the reconstructed uptake, not likely to alter 




MEAN UPTAKE RELATIVE DIFFERENCES W.R.T. CT REFERENCE  
 SUVMEAN SUVRMEAN 
 Atlas ZTE Atlas ZTE 
Mean -1% -6% +6% -5% 
Stdv. +17% +8% +16% +8% 
Min -29% -23% -22% -22% 
Max +37% +7% +40% +12% 
Trend y=0.99x y=0.95x y=1.06x y=0.96x 
R2 0.93 0.98 0.80 0.92 
 
TABLE II 
MAX UPTAKE RELATIVE DIFFERENCES W.R.T. CT REFERENCE  
 SUVMAX SUVRMAX 
 Atlas ZTE Atlas ZTE 
Mean  -1% -5%  +5% -4% 
Stdv.  +14% +7%  +13% +8% 
Min  -25% -24%  -17% -23% 
Max  +32% 5%  +35% +16% 
Trend  y=1.04x y=0.97x  y=1.04x y=0.98x 
R2 0.88 0.93 0.77 0.90 
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Fig. 5. Scatter plot of the pituitary mean SUVR values obtained, for each 
subject, with the MR-based attenuation correction methods (abcissae), 
compared to the CT-based reference method (ordinate). 
DISCUSSION 
This is the first reported clinical evaluation of the impact of 
advanced attenuation correction methods on PET/MR pituitary tumor 
diagnosis. The results suggest that attenuation correction using zero 
echo time MR sequences does indeed improve the accuracy of 11C-
Methionine PET imaging with respect to the current default atlas 
method.  
Accurate lesion localization within the pituitary gland was possible 
with the proposed protocol. The availability of simultaneously 
acquired, well-aligned high-resolution morphological information 
from MR facilitated the interpretation and quantitative analysis of PET 
findings. This is of particular relevance, given the critical nature of 
transsphenoidal surgical excision: both incomplete tumor removal and 
excessive removal of healthy pituitary tissue result in permanent 
sequelae requiring costly medication and severely affecting quality of 
life. Accurate identification of the adenoma with PET within the high-
resolution anatomical context provided by MR can be instrumental for 
successful surgical guidance. 
While the results confirm that ZTE-based attenuation correction 
offers increased accuracy compared to the default atlas-based method, 
the improvement is neither as marked nor as consistent as in previously 
reported studies [25]–[27]. This is due to the challenging location of 
the pituitary gland, directly behind the nasal passages and above the 
sphenoid sinus. These are known to be difficult regions for the pseudo-
CT generation algorithm, due to the abundance of air-tissue interfaces 
where partial volume effects are susceptible of being misclassified as 
bone. A potential solution to this problem is the use of novel Deep 
Learning algorithms, which have been recently shown to provide very 
promising segmentation results for this area [28].    
Further work will be aimed at improving the resolution of the bone 
maps, in order to achieve not only more accurate attenuation correction 
-by drastically reducing the partial volume effect- but also potentially 
useful bone maps for surgical planning. 
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